Literature DB >> 11834769

Costs of aspirin and statins in general practice.

A Drummond1, S Kwok, J Morgan, P N Durrington.   

Abstract

BACKGROUND: Aspirin and statins are the two drugs most commonly indicated for secondary prevention of atherosclerotic disease in the UK. Statin treatment, which is more expensive, is under-prescribed. AIM: To assess the expenditure in Greater Manchester general practices on aspirin and statins.
DESIGN: Survey of general practice records.
METHODS: Practice registers were searched for patients receiving regular prescriptions for aspirin. For each patient, the next patient of the same sex, aged within +/- 5 years, not on aspirin, acted as a control. Details of all medications were recorded. In a sub-study, records of 100 patients on aspirin were studied to determine indications for aspirin prescription.
RESULTS: There were 1003 (511 men, 492 women) in each group; mean age was 70 years in both groups. In the sub-study, 79% of patients received aspirin for established vascular disease, 9% for hypertension, 5% for diabetes mellitus, 5% for unknown reasons and 2% for arthritis. Of the patients on aspirin, 67% received dispersible aspirin 75 mg/day. The rest were on higher doses (10%) or on more expensive preparations (22%), costing up to 22.4 p/day. The mean daily cost of aspirin was 1.7p. Dyspepsia treatment was received by 266 patients and 194 controls (p<0.001). There was a wide range of dyspepsia medications (10-306p/day), averaging in the groups as a whole 15.5p/day in patients and 12.5p/day in controls. Of the patients on aspirin, 28% received statins, compared to 4% of controls. Mean daily expenditure on statins in patients was 23.4p.
CONCLUSION: Assuming the difference in the use of medication for dyspepsia between patients and controls was due to aspirin, the full cost of aspirin treatment was 4.7p/day. Statins were probably under-prescribed in aspirin-takers, many of whom would have been at high CHD risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834769     DOI: 10.1093/qjmed/95.1.23

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  4 in total

1.  American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively.

Authors:  P McElduff; M Jaefarnezhad; P N Durrington
Journal:  Heart       Date:  2006-05-22       Impact factor: 5.994

2.  Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

Authors:  S V Morant; A D McMahon; J G F Cleland; P G Davey; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

3.  Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.

Authors:  Joshua Pink; Steven Lane; Munir Pirmohamed; Dyfrig A Hughes
Journal:  BMJ       Date:  2011-10-31

4.  Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.

Authors:  Randall S Stafford; Veronica Monti; Jun Ma
Journal:  PLoS Med       Date:  2005-11-15       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.